A phase 3 study to determine the efficacy and safety of recombinant human activated protein C in severe sepsis
Completed
- Conditions
- Severe sepsisInfections and InfestationsSepsis
- Registration Number
- ISRCTN74215569
- Lead Sponsor
- Eli Lilly and Company (USA)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1690
Inclusion Criteria
Not provided at time of registration
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration